Trial Profile
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Apr 2024 Planned End Date changed from 19 Jul 2027 to 22 Feb 2025.
- 23 Jun 2022 Planned End Date changed from 1 Aug 2022 to 19 Jul 2027.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology